Skip to main content
Premium Trial:

Request an Annual Quote

Techne Acquires 39 Percent Stake in Discovery Genomics

NEW YORK, Aug. 3 – Biotech holding company Techne has acquired a 39 percent interest in Discovery Genomics and rights to develop antibodies and immunoassays for proteins targets that Discovery Genomics discovers, Techne said on Friday.

The agreement allows Techne exclusively to sell products based on Discovery Genomics’ discoveries in the research market royalty-free. Techne may also opt to sell similar products in the diagnostic market with obligations to pay royalties to Discovery Genomics.

Techne said in a statement that the company would classify a portion of Discovery Genomics’ losses as a Techne research expense. Techne predicted those losses would not exceed $1 million during the first year, and $2 million during the second and third year.

Techne also obtained warrants to acquire additional equity in Discovery Genomics.

Financial details of the deal were not disclosed. 

Minneapolis, Minn.-based Techne controls Research and Diagnostic Systems and R&D Systems, headquartred in Abingdon, UK. Both companies manufacture and distribute research and diagnostic biotechnology products. 

Discovery Genomics, also based in Minneapolis, has licensed gene knock-down and transposon technology from the University of Minnesota for applications in functional genomics and drug discovery. 

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.